This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nabbout, R. C. Articles by Dulac, O. Search for Related Content PubMed PubMed Citation Articles by Nabbout, R. C. Articles by Dulac, O. Social Bookmarking                         What's this?

Vigabatrin in Partial Seizures in Children

Department of Pediatric Neurology, Hôpital Saint Vincent de Paul, Paris, France

Catherine Chiron, MD, PhD

Department of Pediatric Neurology, Hôpital Saint Vincent de Paul, Paris, France

John Mumford, MD

Marion Merrell Dow, Winnersh, UK

Caroline Dumas, MD

Marion Merrell Dow S.A., Levallois-Perret, France

Olivier Dulac, MD

Department of Pediatric, Neurology Hôpital Saint Vincent de Paul, Paris, France

Patients with partial seizures aged 1 week to 19 years (n = 175) were included in several prospective vigabatrin studies at the hospital Saint Vincent de Paul. A decrease in seizure frequency of over 50% was achieved in 70% of patients, with 30% becoming seizure free, and only 6% experiencing an increase. Tuberous sclerosis gave the best response (85%), tumors the lowest (45%), the usual figure for other causes being 70%. Patients with malformations were the most likely to experience seizure increase. Regarding topography of focus, the lowest rate of seizure-free patients was in rolandic foci. Early treatment produced better results. Infants experienced the highest rate of response, but also of relapse, the latter occurring mainly between 6 months and 1 year. The incidence of loss of efficacy depended on etiology and topography of focus, tumors and frontal foci having the highest risk. Occurrence of new seizures was more frequent in young patients with tuberous sclerosis, the third experiencing status epilepticus. Vigabatrin monotherapy could only be achieved in 33% of seizure-free patients, reduction of comedication being a risk of relapse and of further intractability. (J Child Neurol 1997;12:172-177).

Journal of Child Neurology, Vol. 12, No. 3, 172-177 (1997)
DOI: 10.1177/088307389701200304


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Milh, N. Villeneuve, F. Chapon, S. Pineau, S. Lamoureux, M.-O. Livet, C. Bartoli, C. Hugonenq, J. Mancini, B. Chabrol, et al. Transient Brain Magnetic Resonance Imaging Hyperintensity in Basal Ganglia and Brain Stem of Epileptic Infants Treated With Vigabatrin J Child Neurol, March 1, 2009; 24(3): 305 - 315. [Abstract] [PDF]

				E. Hancock and J. P. Osborne Topical Review: Vigabatrin in the Treatment of Infantile Spasms in Tuberous Sclerosis: Literature Review J Child Neurol, February 1, 1999; 14(2): 71 - 74. [Abstract] [PDF]